Literature DB >> 3004518

The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation.

J Nilsson, M Sjölund, L Palmberg, A M Von Euler, B Jonzon, J Thyberg.   

Abstract

Migration of smooth muscle cells from the media to the intima of the arterial wall and proliferation of intimal smooth muscle are major early events in the formation of an atherosclerotic lesion. The start of proliferation requires that the cells have passed through a modulation from contractile to synthetic phenotype and that they are stimulated with growth factors. Here, we have examined the effects of the calcium antagonist nifedipine on phenotypic modulation and growth of isolated rat arterial smooth muscle cells cultivated in vitro. The results indicate that micromolar concentrations of nifedipine slow down the rate of transformation of the cells from a contractile to a synthetic phenotype and inhibit initiation of DNA synthesis as well as cellular proliferation. The inhibitory effect on DNA synthesis was seen both in cells stimulated with whole blood serum and with purified platelet-derived growth factor. The results raise the possibility that nifedipine may be used to prevent atherogenesis and to inhibit progression of fibromuscular lesions by interfering with the proliferation of arterial smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3004518     DOI: 10.1016/0021-9150(85)90059-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  27 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

Review 3.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

4.  Effect of metabolic syndrome and aging on Ca2+ dysfunction in coronary smooth muscle and coronary artery disease severity in Ossabaw miniature swine.

Authors:  Jill K Badin; Rebecca S Bruning; Michael Sturek
Journal:  Exp Gerontol       Date:  2018-05-03       Impact factor: 4.032

5.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 6.  Influence of nifedipine on experimental arteriosclerosis.

Authors:  A M Knorr; S Kazda
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

7.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.

Authors:  K S Woo; C O Pun
Journal:  West J Med       Date:  1990-02

9.  Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats.

Authors:  T Hérembert; D L Zhu; P Marche
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

10.  The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis.

Authors:  F Akimoto
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.